The normal functions of peptides that aggregate in Alzheimer’s, Parkinson’s, and Huntington’s have been largely overlooked by scientists, but some argue that they are critical for understanding the development of disease.

Niacin, a form of vitamin B3 used to treat cardiovascular disease, helps immune cells in the brain fight neurodegenerative diseases such as Alzheimer’s in mice models, according to recent studies. Researchers hope that human clinical trials will swiftly follow.

His work was pivotal to understanding the mechanisms of neurodegenerative diseases, particularly Alzheimer’s and Parkinson’s.

Researchers provide evidence that the Alzheimer’s-associated protein calibrates a signaling pathway that is conserved across the animal kingdom.

Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear.

A new study links a variant of the apolipoprotein E gene called APOE ε4 to better memory in older age, even in the presence of amyloid plaques—a possible explanation for the variant’s persistence despite its association with an increased risk of Alzheimer’s disease.

Pharmaceutical companies ramp up efforts to get the brain’s immune cells to help treat Alzheimer’s disease and other conditions, but not everyone agrees the approach will be effective.

A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.

A dysfunctional lymphatic system, described as a clogging of the brain’s sink, may explain why immunotherapies fail in some Alzheimer’s patients.

The test will be a cheaper and more accessible alternative to currently available diagnostic tools, researchers say.

These “coarse-grained” plaques resemble those that clog up the brain’s blood vessels in a different disease, pointing to links between the vascular system and the neurodegenerative disease.

Accumulation of the protein was more likely to be found in the brains of people who slept less well years earlier, according to a new study.

New studies show that elevated levels of a form of tau called p-tau217 can accurately distinguish Alzheimer’s disease from other forms of dementia, and perhaps even predict it.

The widely expected move comes months after the companies scrapped trials of another Alzheimer’s drug.

Exposing mice to an hour of 40-hertz stimuli every day for a week reduced levels of amyloid-β plaques and tau protein, and improved cognition.

The test uses levels of plasma amyloid-β to estimate the buildup of protein plaques in the brain.

The once fringe idea is gaining traction among the scientific community.

Emerging evidence links bacterial or viral infection with the neuropathology of Alzheimer’s disease.